摘要
血管内大B细胞淋巴瘤是弥漫大B细胞淋巴瘤的罕见亚型,以血管腔内淋巴瘤细胞异常增殖、高度侵袭性、致死率高为主要特点。其临床表现在东西方不同地区间是有差别的。免疫表型在诊断和鉴别诊断中起重要作用。CHOP方案化疗联合利妥昔单抗(rituximab)治疗可以提高生存率,大剂量化疗(HDC)并自体外周血造血干细胞移植(Auto-HSCT)的强化治疗可以改善预后。
Intravascular large B-cell lymphoma （IVLBCL） is a rare form of diffuse LBCL characterized by preferential intravascular growth of malignant lymphocytes, aggressive behavior, and an often fatal course. It displays some differences in clinical presentation among diverse geographical areas. The immu- nophenotype plays a critical role in diagnosis and differential diagnosis. Recent therapeutic approaches, such as the rituximab plus CHOP regimen, could have a positive impact in IVLBCL patients. The use of high-dose chemotherapy supported by autologous stem-cell transplantation may improve current outcomes.
出处
《医学研究生学报》
CAS
2008年第2期207-209,214,共4页
Journal of Medical Postgraduates
基金
江苏省六大人才高峰重点课题基金资助项目(批准号:2005A3)
关键词
血管内大B细胞淋巴瘤
诊断
治疗
Intravascular large B-cell lymphoma
Diagnosis
Theatment
